Susie Wyss used to inject herself daily with a medication for multiple sclerosis. “The injection hurt. It caused welts, ...

Intranasal foralumab can modulate a number of immune cell types in people with non-active SPMS, developer Tiziana Life ...

Formerly believed to predominantly affect Caucasians, new research indicates that MS actually may hit Blacks the hardest.

Researchers at the University of Colorado Anschutz Medical Campus have found a promising drug candidate that could help ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use ...

A promising new treatment accelerates myelin repair, potentially restoring vision and improving brain function in people with ...

Relapsing-remitting multiple ... relapses of new or worsening MS symptoms. These relapses can last for days or months until symptoms slowly improve, with or without treatment.

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that ...

Researchers at the University of Colorado Anschutz Medical Campus have identified LL-341070, a promising drug candidate that ...

The study identified gene expression changes which were detected beginning three months after intranasal dosing of foralumab in our ongoing ISPPEA (or expanded access program). Key findings include ...